Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 12 of 24 pages ‹ First < 10 11 12 13 14 > Last ›
HSL680
Guyatt G.
Guidelines for interaction with the pharmaceutical industry
CMAJ 1995; 152:1041-1042
HSL681
Guyatt G.
L’enseignement de la médeicne et l’ industrie pharmaceutique
CMAJ 1995; 152:1039-1040
HSL684
Eldridge A.
Sponsorship and the RMI Code of Practice
N Z Med J 1995; 108:279
HSL687
de Serres J.
L’enseignement de la médeicne et l’ industrie pharmaceutique
CMAJ 1995; 152:1039
HSL688
Dasta JF, Visconti JA, Hawksworth K.
The adoption of clarithromycin by university-based physicians during its first year of commercial availability
J Pharm Mark Manage 1995; 9:(3):3-20
HSL1424
Choo V.
Attempted ghostly dishonesty
Lancet 1995; 345:643
HSL1445
Chetley A.
OTC advertising: in whose interest? A consumer’s viewpoint
WHO Drug Information 1995; 9:(1):10-11
HSL1446
Cárdenas EZ, Isenrich LL.
Prescribing habits of Peruvian physicians and factors influencing them
Bulletin of PAHO 1995; 29:328-337
HSL1451
Beales JH 3rd, MacLeod WC.
Assessments of pharmaceutical advertisements: a critical analysis of the criticism.
Food Drug Law J 1995; 50:(3):415-49
HSL1453
Barnett AA.
FDA scrutinises drug firms’ new connections
Lancet 1995; 346:1151
HSL1454
Barnett AA.
FDA takes aim at financial bias in research
Lancet 1995; 346:299
HSL1455
Bardelay D, Bécel B.
Visits from medical representatives: fine principles, poor practice
Prescrire International 1995; 4:(18):120-122
HSL1457
Andaleeb SS, Tallman RF.
Physician attitudes toward pharmaceutical sales representatives.
Health Care Manage Rev 1995 Sum; 20:(3):68-76
HSL1843
Ekedahl A, Andersson SI, Hovelius B, Molstad S, Liedholm H, Melander A.
Drug prescription attitudes and behaviour of general practitioners. Effects of a problem-oriented educational programme
Eur J Clin Pharmacol 1995; 47:(5):381-7
HSL2067
Ogilvy D.
Ogilvy on advertising.
London: Prion 1995
http://www.randomhouse.com/vintage/catalog/display.pperl?isbn=9780394729039
HSL2093
Branthwaite A, Downing T.
Marketing to doctors - the human factor.
Scrip Magazine 1995; 32-5
HSL5337
Guell RC, Fischbaum M.
Toward allocative efficiency in the prescription drug industry.
Milbank Q 1995; 73:(2):213-30
HSL6552
Tanzania moves to control drug promotion
Essential Drugs Monitor 1995; (20):16
HSL6553
US fraud alert targets unethical promotion
Essential Drugs Monitor 1995; (20):16
HSL6554
Bardelay D.
More on visits by sales reps
Essential Drugs Monitor 1995; (19):9
HSL6555
Buhl F.
More on visits by sales reps
Essential Drugs Monitor 1995; (19):9
HSL6556
Chetley A.
Problem drugs
London: HAI/Zed Books 1995
www.haiweb.org
HSL6557
Editor .
BMJ should declare its own conflict of interest
BMJ 1995; 311:878-879
HSL6558
Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP.
Drug promotion
New England Journal of Medicine 1995; 332:1033
HSL6560
Kopp C.
Reps on the hot seat
Prescrire International 1995; 4:(18):128
HSL6562
Moore TJ.
Deadly medicine: why tens of thousands of heart patients died in America’s worst drug disaster
New York: Simon & Shuster 1995
HSL6563
Shashindran CH, Sethuraman KR.
Drug promotion: push, promote or educate
Essential Drugs Monitor 1995; (20):24
HSL6564
Squires BP.
Medical newsletters: funding and interests should be stated
Canadian Medical Association Journal 1995; 152:1745
HSL6565
Stern RS.
Drug promotion
New England Journal of Medicine 1995; 332:1033
HSL6566
Bayer asserts that we should use “Ciproxin first for difficult infections
MaLAM Australian News 1995; 3:(1):1-2
HSL6590
Nightingale SL.
Written patient information on prescription drugs: The evolution of government and voluntary programs in the United States
Int J Technol Assess Health Care 1995; 11:(3):399-409
HSL6592
Wyeth claims that Polymagma “works fast by flushing out diarrhea-causing bacteria”
MaLAM International News 1995; 13:(7):1
HSL6600
From lobbying to activism: overstepping the mark
Health Horizons 1995; (26):23
HSL6615
Drug promotion: Sri Lanka’s new ethical criteria
Essential Drugs Monitor 1995; (22):2
http://www.who.int/medicines/pdf/edm24_en.pdf
HSL8329
Hemeryck L, Chan R, McCormack PM, Condren L, Feely J.
Pharmaceutical advertisements in Irish medical journals
Journal of Pharmaceutical Medicine 1995; 5:(3-4):147-151
HSL9037
Abraham J.
Science, Politics And The Pharmaceutical Industry: Controversy And Bias In Drug Regulation
London: Routledge 1995
http://www.routledge.com/shopping_cart/products/product_detail.asp?sku=&isbn=9781857282009&parent_id=&pc=/shopping_cart/search/search.asp?
HSL9039
Chowdhury Z.
The politics of essential drugs. The makings of a successful health strategy: lessons from Bangladesh.
London: Zed Books/Dag Hammarskjold Foundation 1995
HSL9141
Smith DL, Basara LR.
Advancing the contribution of the patient and the caregiver to prescription medication compliance
Journal of Pharmacoepidemiology 1995; 3:(2):63-85
HSL9150
Ukens C.
Scorecard puts generics ahead so far this year
Drug Topics 1995; 139:(139):
HSL9151
Petersen C.
Direct-to-consumer drug ads gain more acceptance
Managed Healthcare 1995; 5:
HSL9163
Kimbel K.
Risk of biased patient information on prescription drugs
International Journal of Risk and Safety in Medicine 1995; 7:(1):
HSL9165
Van Trigt AM, De Jong Van Den Berg LT, Willems J, Tromp TF, Haaijer Ruskamp FM.
Pharmaceutical industry and the lay press: industry's point of view
International Journal of Risk and Safety in Medicine 1995; 7:(1):1-15
HSL9179
Sakurai Y, Kugai N, Kawana T, Fukita T, Fukumoto S.
Comprehensive adverse events management system for the pharmaceutical industry: Takeda Trac System
Drug Information Journal 1995; 29:(2):645-659
HSL9180
Bolger G.
Communicating drug quality observations
Drug Information Journal 1995; 29:(2):563-569
HSL9189
Amery WK, Van Winkel M.
Patient package inserts for prescription drugs in an international pharmaceutical company
Drug Information Journal 1995; 29:(1):51-60
HSL9197
Fallowfield JM.
Adverse drug reactions from database to prescriber: United Kingdom experience
Drug Information Journal 1995; 29:(1):327-333
HSL13269
Cobb-Walgren CJ, Ruble C, Donthu N.
Brand Equity, Brand Preference, and Purchase Intent
Journal of Advertising 1995 Fall; 24:(3):25-40
http://mesharpe.metapress.com/app/home/journal.asp?referrer=parent&backto=linkingpublicationresults,1:110658,1&linkin=633419879548048699
HSL15405
Kerr S.
On the folly of rewarding A, while hoping for B
Academy of Management Executive 1995; 9:(1):
http://books.google.com.au/books?id=dxCjoSU4MnwC&pg=PA143&lpg=PA143&dq=Consider,+however,+some+critical+differences+in+the+reward+system+in+use+during+the+two+conflicts.+What+did+the+GI+in+World+War+II+want?+To+go+home.+And+when+did+he+get+to+go+home?+When+the+war+was+won!+If+he+disobeyed+the+orders+to+clean+out+the+trenches+and+take+the+hills,+the+war+would+not+be+won+and+he+would+not+go+home.+Furthermore,+what+were+his+chances+of+attaining+his+goal+(getting+home+alive)+if+he+obeyed+the+order+s+compared+to+his+chances+if+he+did+not?+What+is+being+suggested+is+that+the+rational+soldier+in+World+War+II,+whether+patriotic+or+not,+probably+found+it+expedient+to+obey.&source=bl&ots=QtIn13F5Qo&sig=mTao2zBuQyldSqbfuyp7HX1F9eI&hl=en&sa=X&ei=D6MTT4nAI8eRiQfYz9BD&ved=0CCEQ6AEwAA#v=onepage&q=Consider%2C%20however%2C%20some%20critical%20differences%20in%20the%20reward%20system%20in%20use%20during%20the%20two%20conflicts.%20What%20did%20the%20GI%20in%20World%20War%20II%20want%3F%20To%20go%20home.%20And%20when%20did%20he%20get%20to%20go%20home%3F%20When%20the%20war%20was%20won!%20If%20he%20disobeyed%20the%20orders%20to%20clean%20out%20the%20trenches%20and%20take%20the%20hills%2C%20the%20war%20would%20not%20be%20won%20and%20he%20would%20not%20go%20home.%20Furthermore%2C%20what%20were%20his%20chances%20of%20attaining%20his%20goal%20(getting%20home%20alive)%20if%20he%20obeyed%20the%20order%20s%20compared%20to%20his%20chances%20if%20he%20did%20not%3F%20What%20is%20being%20suggested%20is%20that%20the%20rational%20soldier%20in%20World%20War%20II%2C%20whether%20patriotic%20or%20not%2C%20probably%20found%20it%20expedient%20to%20obey.&f=false
HSL15820
Rodwin MA.
Medicine Money & Morals: Physicians' Conflicts of Interest
: Oxford University Press 1995
http://www.oup.com.au/titles/academic/health_sciences/9780195096477
HSL15848
Liu SS.
A comparison of pharmaceutical promotional tactics between Hong Kong and China
Journal of Business & Industrial Marketing 1995; 10:(1):34 - 43
http://www.emeraldinsight.com/Insight/viewContentItem.do;jsessionid=EE6368BEBD17602F73081DBF99621C79?contentType=Article&contentId=856643
HSL19864
Shashindarn CH, Sethuraman KR
Drug Promotion: push, promote or educate?
Essential Drugs Monitor 1995; (20):24
http://apps.who.int/medicinedocs/fr/d/Js16517e/2.2.html#Js16517e.2.2
HSL19868
Petroshius SM, Titus PA, Hatch KJ
Physician attitudes toward pharmaceutical drug advertising
Journal of Advertising Research 1995; 35:(6):41
HSL20017
Perry RF
Physicians and Pharmaceutical Sales Representatives
JAMA 1995; 274:(16):1267
http://jama.ama-assn.org/content/274/16/1267.1
HSL2061
Ferner RE, Scott DK.
Whatalotwegot--the messages in drug advertisements.
BMJ 1994 Dec 24-31; 309:(6970):1734-6
http://www.bmj.com/cgi/content/full/309/6970/1734
HSL19972
Appleton DR
Cross Words
BMJ 1994 Dec 24; 309:1737
http://www.bmj.com/content/309/6970/1737
HSL9220
Specific requirements on content and format of labeling for human prescription drugs; revision of pediatric use subsection in the labeling; final rule
Federal Register 1994 Dec 13; 59:64240-64250
HSL9210
Gannon K, Muirhead G, Ukens C, Rosendahl I, Schalow A.
Annual business outlook: will 1995 really be as good as it looks?
Drug Topics 1994 Dec 12; 138:82-84, 87-90, 92, 94-95, 99
HSL5727
Carandang ED, Moulds RF.
Pharmaceutical advertisements in Australian medical publications--have they improved?
Med J Aust 1994 Dec 5-19; 161:(11-12):671-2
HSL5428
Naimark D, Naglie G, Detsky AS.
The meaning of life expectancy: what is a clinically significant gain?
J Gen Intern Med 1994 Dec 01; 9:(12):702-7
HSL6149
Lexchin J.
Agents against pediatric diarrhea. Assessing the information companies supply to Canadian physicians
Can Fam Physician. 1994 Dec 01; 40:2082-7
HSL9236
Talley CR.
Patient autonomy and drug therapy adherence
American Journal of Hospital Pharmacy 1994 Dec 1; 51: 2913
HSL6544
Health highlights of the 14th IOCU World Congress
HAI News 1994 Dec
HSL6545
Sadly predictable unethical promotion
HAI Europe Update 1994 Dec; 4:(2):1-2
HSL6546
Chambliss ML.
Is pharmaceutical marketing valuable?
Arch Fam Med 1994 Dec; 3:(12):1032-3
HSL6547
Deamer RL.
Value and need for pharmaceutical promotion disputed.
Arch Fam Med 1994 Dec; 3:(12):1033
HSL6548
Goldstein AO, Ives TJ.
Pharmacoeconomic considerations in pharmaceutical company promotions.
Arch Fam Med 1994 Dec; 3:(12):1034-5
HSL6550
Shaughnessy AF, Slawson DC, Bennett JC.
Pharmaceutical advertising: the FDA does not protect us.
Arch Fam Med 1994 Dec; 3:(12):1031
HSL6551
Thompson RS.
Pharmaceutical marketing.
Arch Fam Med 1994 Dec; 3:(12):1031-2
HSL9209
Stephenson J.
Commercial confidence: secrecy or openness?
Pharmaceutical Executive 1994 Dec; 14:24, 26
HSL9219
Bohmer K, Feinberg JL.
Rose by any other name: kickbacks vs cognitive services
Consultant Pharmacist 1994 Dec; 9:1400-1401, 1405-1406
HSL9243
Sukkari SR, Sasich LD, Nicholls PJ.
Promoting research to the medical staff: reorganized hospital formulary as a key element in the transfer of scientifically relevant drug information
ASHP Midyear Clinical Meeting 1994 Dec; 29:P-347
HSL9244
Fehring RA.
Impact of managed care: pharmaceutical industry analyst perspective
ASHP Midyear Clinical Meeting 1994 Dec; 29:
HSL12876
Sakson S.
Drugmaker Will Manage Diseases to Keep People Healthy, Sell More Drugs
The Associated Press 1994 Nov 29
HSL6040
Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP.
Therapeutic-class wars--drug promotion in a competitive marketplace.
N Engl J Med 1994 Nov 17; 331:(20):1350-3
HSL6462
Stern RS.
Drug promotion for an unlabeled indication--the case of topical tretinoin.
N Engl J Med 1994 Nov 17; 331:(20):1348-9
http://content.nejm.org/cgi/content/extract/331/20/1348
HSL5906
Forrest JB.
Faculties of health sciences and the pharmaceutical industry: an effective partnership.
CMAJ 1994 Nov 1; 151:(9):1320-2
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=7954182
HSL6027
Guyatt G.
Health sciences and the pharmaceutical industry: partnerships can be effective and ethical.
CMAJ 1994 Nov 1; 151:(9):1323-5
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=7954183
HSL6039
Keng A, Coley RM.
Evaluating the accuracy of citations in drug promotional brochures.
Ann Pharmacother 1994 Nov; 28:(11):1231-5
HSL6538
SmithKline Beecham: Is there “evidence of something amiss”?
MaLAM International News 1994 Nov; 12:(8):1-2
HSL6539
We can all learn something from SmithKline Beecham’s medical education programme for Augmentin
MaLAM Australian News 1994 Nov; 2:(4):1
HSL6540
What’s in a name? Credibility and profit
Consumer Reports 1994 Nov688
HSL6541
Harvey M.
Fairy tales can come true
Pharmaceutical Executive 1994 Nov26-30
HSL6542
Mansfield P.
Re: the promotion of Augmentin (amoxycillin/clavulanic acid)
1994 Nov;
HSL6543
Vicciardo L.
Interesting times for US sales forces
Scrip Magazine 1994 Nov; (29):52-54
www.pjbpubs.co.uk/scrip/scrhome.html
HSL9184
Indospray rescheduled from S4 to S2
Australian Journal of Pharmacy 1994 Nov; 74:992-993
HSL9217
Dudley JW.
Market about to boom: why European OTC growth will outpace growth in the United States by 2000
Pharmaceutical Executive 1994 Nov; 14:48, 50, 52, 54
HSL9218
Benzing L, MacKelvie CF.
Coping with patient privacy: prescription for the pharmaceutical industry
Pharmaceutical Executive 1994 Nov; 14:64, 66, 68-70, 72, 74
HSL19747
APhA on 'bounties' to pharmacists
Scrip 1994 Oct 28; (1970):17
HSL6437
Nahata MC.
More conflicts of interest: review articles sponsored by the pharmaceutical industry.
JAMA 1994 Oct 26; 272:(16):1253-4
HSL6537
Control of drug advertising in Canada
Ottawa: Drugs Directorate 1994 Oct 25
HSL5900
Dikshit RK, Dikshit N.
Commercial source of drug information: comparison between the United Kingdom and India.
BMJ 1994 Oct 15; 309:(6960):990-1
http://www.bmj.com/cgi/content/full/309/6960/990
HSL6456
Sherman B.
Indications for growth hormone.
Lancet 1994 Oct 15; 344:(8929):1095
HSL6536
Pendergast MK
Statement before the Subcommittee on Regulation, Business Opportunities, and Technology Committee on Small Business, U.S. House of Representatives
Rockville, Maryland: Food and Drug Administration 1994 Oct 12
HSL6440
Parmley WW.
The pharmaceutical industry under attack.
J Am Coll Cardiol 1994 Oct; 24:(4):1143-4
HSL6455
Shaughnessy AF, Slawson DC, Bennett JH.
Separating the wheat from the chaff: identifying fallacies in pharmaceutical promotion.
J Gen Intern Med 1994 Oct; 9:(10):563-8
HSL6528
Miles Canada launches nation-wide physician-patient communication program
PMAC News 1994 Oct; 3-4
HSL6529
Searle partners with the Arthritis Society to help Canadians cope with arthritis
PMAC News 1994 Oct; 5
HSL6530
Wellcome claims that Zovirax is “a way to make a difference” in varicella
MaLAM International News 1994 Oct; 12:(7):1-2
HSL6531
What drug companies know
Consumer Reports 1994 Oct631
HSL6532
Self-regulation or self-deception? Commentary on the 1994 revision of the IFPMA Code of Pharmaceutical Marketing Practices
Amsterdam: Health Action International 1994 Oct
Page 12 of 24 pages ‹ First < 10 11 12 13 14 > Last ›
